SignatureFD’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-235
| Closed | -$714 | – | 3488 |
|
|
2024
Q4 | $714 | Buy |
235
+144
| +158% | +$627 | ﹤0.01% | 3087 |
|
|
2024
Q3 | $472 | Sell |
91
-12
| -12% | -$60 | ﹤0.01% | 3106 |
|
|
2024
Q2 | $265 | Sell |
103
-458
| -82% | -$1.56K | ﹤0.01% | 3040 |
|
|
2024
Q1 | $2.76K | Buy |
561
+104
| +23% | +$616 | ﹤0.01% | 2710 |
|
|
2023
Q4 | $4.02K | Sell |
457
-381
| -45% | -$3.12K | ﹤0.01% | 2572 |
|
|
2023
Q3 | $9.61K | Sell |
838
-555
| -40% | -$10.7K | ﹤0.01% | 2227 |
|
|
2023
Q2 | $35.3K | Hold |
1,393
| – | – | ﹤0.01% | 1607 |
|
|
2023
Q1 | $44.9K | Buy |
1,393
+1,237
| +793% | +$38.6K | ﹤0.01% | 1449 |
|
|
2022
Q4 | $2.88K | Sell |
156
-91
| -37% | -$2.08K | ﹤0.01% | 2678 |
|
|
2022
Q3 | $7K | Buy |
247
+138
| +127% | +$2.8K | ﹤0.01% | 2296 |
|
|
2022
Q2 | $2K | Buy |
109
+24
| +28% | +$369 | ﹤0.01% | 2831 |
|
|
2022
Q1 | $2K | Sell |
85
-275
| -76% | -$4.17K | ﹤0.01% | 2886 |
|
|
2021
Q4 | $6K | Buy |
360
+294
| +445% | +$4.9K | ﹤0.01% | 2362 |
|
|
2021
Q3 | $2K | Sell |
66
-15
| -19% | -$428 | ﹤0.01% | 2729 |
|
|
2021
Q2 | $2K | Buy |
81
+15
| +23% | +$433 | ﹤0.01% | 2637 |
|
|
2021
Q1 | $2K | Hold |
66
| – | – | ﹤0.01% | 2552 |
|
|
2020
Q4 | $2K | Hold |
66
| – | – | ﹤0.01% | 2334 |
|
|
2020
Q3 | $2K | Hold |
66
| – | – | ﹤0.01% | 2297 |
|
|
2020
Q2 | $2K | Hold |
66
| – | – | ﹤0.01% | 2214 |
|
|
2020
Q1 | $1K | Hold |
66
| – | – | ﹤0.01% | 2228 |
|
|
2019
Q4 | $1K | Hold |
66
| – | – | ﹤0.01% | 2131 |
|
|
2019
Q3 | $1K | Hold |
66
| – | – | ﹤0.01% | 2035 |
|
|
2019
Q2 | $1K | Buy |
+66
| New | +$832 | ﹤0.01% | 1971 |
|
Other funds holding RVNC
SignatureFD's RVNC Position: Q1 2025 in Review
SignatureFD sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 235 shares — an estimated $714 sold.
SignatureFD first reported a position in RVNC in Q2 2019 and held it in 23 quarters. The position peaked at $44.9K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- SignatureFD reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- SignatureFD sold 235 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $714.
- SignatureFD first reported a position in Revance Therapeutics, Inc. in Q2 2019 and held it in 23 quarters.
- SignatureFD's Revance Therapeutics, Inc. position peaked at $44.9K in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on SignatureFD's 13F filing for Q1 2025, filed 2 May 2025.